CU23419A1 - NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS - Google Patents

NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS

Info

Publication number
CU23419A1
CU23419A1 CU20030284A CU20030284A CU23419A1 CU 23419 A1 CU23419 A1 CU 23419A1 CU 20030284 A CU20030284 A CU 20030284A CU 20030284 A CU20030284 A CU 20030284A CU 23419 A1 CU23419 A1 CU 23419A1
Authority
CU
Cuba
Prior art keywords
nmb0088
protein
formulations
inducing
antigen
Prior art date
Application number
CU20030284A
Other languages
Spanish (es)
Inventor
Garcia Gretel Sardinas
Menendez Evelin Caballero
Diaz Darien Garcia
Negrin Yasser Perera
Nunez Lazaro Hiram Betancourt
Perez Olivia Niebla
Feyt Rolando Pajon
Blanco Sonia Gonzalez
Nieto Gerardo Enrique Guillen
Serra Lila Rosa Castellanos
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20030284A priority Critical patent/CU23419A1/en
Publication of CU23419A1 publication Critical patent/CU23419A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patógenos. Para lograr este objetivo se aisló e identificó la proteína NMB0088 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente se clonó y expresó el gen codificante para la proteína NMB0088, la cual se puificó evaluándose luego su inmunogenicidad en biomedelos animales. El secuenciamiento de genes homólogos evidenció, por su elevado grado de conservación, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. LAs formulaciones resultantes de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.Use of a new vaccine antigen applied in a preventive or therapeutic way against bacterial, viral, cancerous or other diseases. The technical objective pursued is the development of formulations capable of raising the protective spectrum of existing vaccines and extending it against different pathogens. To achieve this objective, the NMB0088 protein was isolated and identified as a component of Neisseria meningitidis external membrane preparations, capable of inducing bactericidal activity. Additionally, the gene coding for the NMB0088 protein was cloned and expressed, which was then puffed and its immunogenicity was evaluated in animal biomedels. The sequencing of homologous genes evidenced, due to its high degree of conservation, its high value as an antigen inducing a cross-immune response when presented by different routes. The formulations resulting from this invention are applicable in the pharmaceutical industry as vaccine formulations for human use.

CU20030284A 2003-12-03 2003-12-03 NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS CU23419A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20030284A CU23419A1 (en) 2003-12-03 2003-12-03 NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030284A CU23419A1 (en) 2003-12-03 2003-12-03 NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS

Publications (1)

Publication Number Publication Date
CU23419A1 true CU23419A1 (en) 2009-09-08

Family

ID=41203572

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030284A CU23419A1 (en) 2003-12-03 2003-12-03 NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS

Country Status (1)

Country Link
CU (1) CU23419A1 (en)

Similar Documents

Publication Publication Date Title
CY1117757T1 (en) MODIFIED RSV F PROTEINS AND METHODS OF USE
NO20044940L (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
CY1119285T1 (en) Adenosine Chimpanzee Vaccine Carriers
CY1108875T1 (en) Mucilage-containing formulas containing xyloglycan and which are useful in medical devices and pharmaceutical formulations
CY1119198T1 (en) STABLE COMPOSITION INCLUDING PTHrP AND USE OF THIS USE
CY1118555T1 (en) GENDER TREATMENT FOR SUBJECTIVE LABORATORY SCIENCE AND OTHER SPINAL DISEASES
WO2007022425A3 (en) Influenza recombinant subunit vaccine
NO20054608L (en) Influenza vaccine
WO2007054283A3 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions
CY1111916T1 (en) VACCINATED VACCINATED ROTAIUS VACCINE FOR ADMINISTRATION OF THE ORAL
AR083561A1 (en) PREPARATION OF AN ANTIGENIC CONSTRUCTION
MX2010012999A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof.
NO20071875L (en) Bicyclic amides as kinase inhibitors
NO20063047L (en) Aqueous ciclesonide suspensions for nebulization
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
BRPI0606614A2 (en) peptides for mucosal vaccine delivery
AR046937A1 (en) PROTEIN NMB0928 AND ITS USE IN PHARMACEUTICAL FORMULATIONS
DE60336588D1 (en) IMPROVED ANTHRAXIMP AND METHOD OF DELIVERY
CU23419A1 (en) NMB0088 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS
CU23435A1 (en) NMB2134 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS
CU23237A1 (en) PROTEIN NMB1125 AND ITS USE IN PHARMACEUTICAL FORMULATIONS
NO20045587L (en) Liposome vaccine formulation for finding fish
BR112014007491A2 (en) amino acid sequences for pathogen control
CU23572A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN NMB0938
AR046921A1 (en) METHOD FOR THE INCORPORATION OF ANTIGENS IN EXTERNAL MEMBRANE VESICULES OF BACTERIA AND RESULTING FORMULATIONS